Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy

This is written in the approval document.

Reimbursement

ODMS

Citation

Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-12-01	Health Service Executive	Indication approved for reimbursement.